Neonatal Infection Clinical Trial
Official title:
Iron and Infection: Neonatal Nutritional Immunity (NeoInnate Study)
The motivation for this study was produced from our preliminary data, which showed that
during the first 96 hours of life a full-term neonate will actively reduce the overall serum
iron concentration of their blood and the transferrin saturation decreases rapidly from 45%
in cord blood to ~20% by six hours post-delivery.
The Investigators hypothesise that this active sequestration of iron, which results in
hypoferremia, is done in an effort to limit susceptibility to infection, a process referred
to as nutritional immunity.
Currently, little is known about iron regulation and iron homeostasis during the first week
of life and even less is known about the comparisons of nutritional immunity between full
term, preterm and low birth weight neonates. Additionally, limited research has been
conducted on the impact of these processes on bacterial pathogens.
In an effort to study the neonatal nutritional immunity and its role in neonatal
susceptibility to infection, The investigator will conduct an observational study in
full-term, preterm and low birth weight vaginally-delivered neonates born at Serrekunda
General Hospital, The Gambia.
The investigators will fully characterise and quantify nutritional immunity during the early
neonatal period and the investogators will assess how this impacts bacterial growth. Study
sensitisation will occur at the antenatal clinic, during the mother's second trimester of
pregnancy. Mothers will be consented and enrolled at delivery. Blood samples will be
collected once from the umbilical cord and at serial time points from the neonates over the
first week of life.
The epicentres of neonatal death worldwide are West and Central Africa, with an estimated 35
deaths per 1000 births. Neonatal infection is the third largest cause of death in children
under five worldwide and is an ongoing major global public health challenge (WHO Millennium
Development Goal 4). Intrauterine and neonatal infections have a high risk of causing
substantial long-term neurological morbidity, affecting not just the individual but the local
community and national productivity. Current research on neonatal sepsis in low-resource
settings is focused on the use of mass perinatal antibiotic therapy for both mothers and
babies. However, antibiotic resistance in the developing world is dramatically increasing and
ablation of the neonatal microbiome has been linked with long-term health consequences. Novel
therapeutic solutions are urgently required.
Nutritional immunity is the process by which the host innate immune system limits nutrient
availability to invading organisms. Iron is an essential micronutrient for both microbial
pathogens and their mammalian hosts. Changes in iron availability and distribution have
significant effects on pathogen virulence and on the immune response to infection. Commonly
found in blood, iron and its moieties (heme) are sequestered mainly in chaperone molecules
(transferrin, lactoferrin, haptoglobin, hemopexin). The long-term goal of our research is to
develop an anti-virulence therapeutic strategy that will augment nutritional immunity in the
at-risk newborn, in order to improve neonatal survival, while avoiding the use of traditional
empirical antibiotics.
During the dynamic neonatal period there are significant changes in circulation, oxygenation
and iron homeostasis, the foetus maintains a high haematocrit to facilitate perfusion in
utero. Within the first week of life, the neonate's haematocrit decreases as the RBCs
containing foetal haemoglobin are broken down. Our preliminary data shows that during the
first 24 hours of life full-term neonates will actively reduce the overall serum iron
concentration and transferrin saturation decreases rapidly from 45% in cord blood to ~20% by
six hours post-delivery.
Currently, little is known about nutritional immunity in the neonates or about its impact on
bacterial pathogens. In the aims below, the investigators will investigate the hypothesis
that nutritional immunity may be an evolutionary mechanism designed to protect neonates from
infection during the first critical days of life, by limiting the pathogenicity and virulence
of these organisms by reducing the availability of iron. The investigators hypothesize that
this protective mechanism may not be activated in preterm and low birth weight neonates,
putting these babies at an enhanced risk of neonatal infection.
Host chaperoned or unchaperoned iron, hemoglobin and heme in the blood can provide a
growth-limiting nutrient to bacterial pathogens depending on the specific bacterial species
and their iron-uptake mechanisms. Bacterial co-evolution with the host has resulted in two
main strategies to combat host nutritional immunity: (1) chelation of iron away from
chaperone proteins with siderophores, and (2) direct uptake of hemoglobin and heme moieties.
Previous research and preliminary experiments conducted by our group, using ex-vivo growth
assays in adult serum, has shown that growth of a panel of neonatal pathogenic bacteria each
decreases in response to decreasing transferrin saturation and increases in response to
increasing hemoglobin concentration. In addition, the investigators have shown that the in
vitro growth of standard laboratory strains of four important causes of early neonatal sepsis
in the developing world (Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, and
Streptococcus agalactiae) is decreased in hypoferremic serum collected from full term
neonates between 6-24 hours after birth compared to serum from the umbilical cord at birth.
In an effort to study neonatal nutritional immunity and its role in neonatal susceptibility
to infection, the investigators will conduct an observational study in full-term (FT),
preterm (PTB) and low birth weight (LBW) vaginally-delivered neonates born at Serrekunda
Hospital in The Gambia. The investigators will fully characterize and quantify nutritional
immunity during the early neonatal period (Research Question 1, Research Question 2 and
Research Question 3) and the investigators will assess how it impacts bacterial growth using
in vitro assays (Research Question 4). Mothers will be consented and enrolled at delivery.
Blood samples will be collected once from the umbilical cord and at serial time points from
the neonates (see sampling schema).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04200807 -
Non-invasive Measurement of Neonatal Central and Peripheral Hemodynamics
|
||
Recruiting |
NCT05695196 -
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant
|
Phase 1 | |
Completed |
NCT01729000 -
Study to Determine if Gloving in Addition to Hand Hygiene Will Prevent Invasive Infections and Necrotizing Enterocolitis
|
N/A | |
Completed |
NCT06413056 -
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection
|
Phase 4 | |
Completed |
NCT03247920 -
Reduction of Intravenous Antibiotics In Neonates
|
Phase 4 | |
Completed |
NCT02486783 -
Infection, Sepsis and Meningitis in Surinamese Neonates
|
N/A | |
Recruiting |
NCT06194396 -
Effect of Chlorhexidine Versus Alcohol on Infections in Neonates
|
N/A | |
Active, not recruiting |
NCT05343403 -
Parental Participation on the Neonatal Ward - the neoPARTNER Study
|
||
Recruiting |
NCT04416373 -
COVID-19 and Pregnancy Outcomes
|
||
Completed |
NCT01540162 -
Experience of Mutaflor Suspension Use in Preterm Infants for Immunity Improvement
|
N/A | |
Withdrawn |
NCT03673566 -
Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO
|
N/A | |
Completed |
NCT04883801 -
Clinical Outcomes of Newborns Born to Pregnant Women With and Without COVID-19
|
||
Terminated |
NCT05379452 -
Outcomes of Neonates Born to Mothers With SARS-CoV-2 Infection in Shanghai
|
||
Active, not recruiting |
NCT04718220 -
Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19
|
N/A | |
Not yet recruiting |
NCT06102044 -
Zinc Supplementation for Young Infants With Clinical Severe Infection in Tanzania
|
Phase 3 | |
Active, not recruiting |
NCT04433364 -
COPE - COVID-19 in Pregnancy and Early Childhood
|
||
Completed |
NCT03383211 -
Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers
|
||
Completed |
NCT04893343 -
Antibiotic Use in a Neonatal Intensive Care Unit Practicing Integrative Medicine
|
||
Withdrawn |
NCT03673579 -
Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - MHSB
|
N/A | |
Completed |
NCT04206878 -
Evaluating the Feasibility of Point of Care Birth Testing in Eswatini
|